The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University provided hypothetical insights on potential stroke-related av...

The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based...

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP...

At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emph...

Recently published study links white matter changes to cognitive decline, emphasizing the cingulum and fornix as key biomarkers for memory loss.

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer...

Scholar Rock’s phase 3 SAPPHIRE trial of apitegromab revealed that the treatment led to improved motor function in patients with spinal muscular atrop...

Panelists discuss how they approach measuring sleepiness in patients with OSA, with emphasis on trusting patient reports over relying solely on object...

Panelists discuss how they select between wake-promoting medications (modafinil, armodafinil, and solriamfetol) by explaining neurotransmitter mechani...

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau...